AllPennyStocks.com Positive Preliminary Findings for Treatment-Resistant Depression

Positive Preliminary Findings for Treatment-Resistant Depression

Positive Preliminary Findings for Treatment-Resistant Depression By: Tomas Ronolski - AllPennyStocks.com News

Thursday, June 2, 2022

Depression is a major illness affecting individuals across the globe. With no known cure, the possibilities of therapies for treatment-resistant depression are an exciting and hopeful prospect.

Medical research company Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF), which provides and advances innovative ketamine and psilocybin treatments for depression and related mental health disorders, announced positive preliminary results from the first Health Canada Approved, Phase II, randomized clinical trial to evaluate the feasibility, safety, tolerability, and efficacy of multi-dose psilocybin-assisted therapy for Treatment-Resistant-Depression per the company’s press release.

The use of psychedelics for mental health treatment is an innovative solution that is gaining traction and is believed to offer professionals another option to treat patients. 

Canadian shares of Braxia ended Wednesday trade higher in a volatile market.


Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Mineral Exploration Company Announces Significant Concentrations of Natural Hydrogen, Shares Move Higher
Record Quarterly Sales Send Shares Of Energy Storage Company Higher
Shares Of This Software Company Found Serious Mid-Week Success
Most Popular


Back to Top